Samir S Taneja1, James Bennett2, Jonathan Coleman3, Robert Grubb4, Gerald Andriole4, Robert E Reiter5, Leonard Marks5, Abdel-Rahmene Azzouzi6, Mark Emberton7. 1. Division of Urologic Oncology, Department of Urology, New York University Langone Medical Center, New York, New York. Electronic address: samir.taneja@nyumc.org. 2. Department of Urology, Emory University Hospital Midtown/Midtown Urology, Atlanta, Georgia. 3. Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Urology, Washington University School of Medicine, St. Louis, Missouri. 5. Department of Urology, University of California at Los Angeles School of Medicine, Los Angeles, California. 6. Department of Urology, Centre Hospitalier Universitaire d'Angers, Angers, France. 7. Division of Surgery and Interventional Science, University College of London, London, United Kingdom.
Abstract
PURPOSE: Vascular targeted photodynamic therapy with WST11 (TOOKAD® Soluble) is a form of tissue ablation that may be used therapeutically for localized prostate cancer. To study dosing parameters and associated treatment effects we performed a prospective, multicenter, phase I/II trial of WST11 vascular targeted photodynamic therapy of prostate cancer. MATERIALS AND METHODS: A total of 30 men with unilateral, low volume, Gleason 3 + 3 prostate cancer were enrolled at 5 centers after local institutional review board approval. Light energy, fiber number and WST11 dose were escalated to identify optimal dosing parameters for vascular targeted photodynamic therapy hemi-ablation. Men were treated with photodynamic therapy and evaluated by posttreatment magnetic resonance imaging and biopsy. Prostate specific antigen, light dose index (defined as fiber length/desired treatment volume), toxicity and quality of life parameters were recorded. RESULTS: After dose escalation 21 men received optimized dosing of 4 mg/kg WST11 at 200 J energy. On posttreatment biopsy residual prostate cancer was found in the treated lobe in 10 men, the untreated lobe in 4 and both lobes in 1. At a light dose index of 1 or greater with optimal dosing in 15 men 73.3% had a negative biopsy in the treated lobe. Six men undergoing retreatment with the optimal dose and a light dose index of 1 or greater had a negative posttreatment biopsy. Minimal effects were observed on urinary and sexual function, and overall quality of life. CONCLUSIONS: Hemi-ablation of the prostate with WST11 vascular targeted photodynamic therapy was well tolerated and resulted in a negative biopsy in the treated lobe in the majority of men. Dosing parameters and the light dose index appear related to tissue response as determined by magnetic resonance imaging and biopsy. These parameters may serve as the basis for further prospective studies.
PURPOSE: Vascular targeted photodynamic therapy with WST11 (TOOKAD® Soluble) is a form of tissue ablation that may be used therapeutically for localized prostate cancer. To study dosing parameters and associated treatment effects we performed a prospective, multicenter, phase I/II trial of WST11 vascular targeted photodynamic therapy of prostate cancer. MATERIALS AND METHODS: A total of 30 men with unilateral, low volume, Gleason 3 + 3 prostate cancer were enrolled at 5 centers after local institutional review board approval. Light energy, fiber number and WST11 dose were escalated to identify optimal dosing parameters for vascular targeted photodynamic therapy hemi-ablation. Men were treated with photodynamic therapy and evaluated by posttreatment magnetic resonance imaging and biopsy. Prostate specific antigen, light dose index (defined as fiber length/desired treatment volume), toxicity and quality of life parameters were recorded. RESULTS: After dose escalation 21 men received optimized dosing of 4 mg/kg WST11 at 200 J energy. On posttreatment biopsy residual prostate cancer was found in the treated lobe in 10 men, the untreated lobe in 4 and both lobes in 1. At a light dose index of 1 or greater with optimal dosing in 15 men 73.3% had a negative biopsy in the treated lobe. Six men undergoing retreatment with the optimal dose and a light dose index of 1 or greater had a negative posttreatment biopsy. Minimal effects were observed on urinary and sexual function, and overall quality of life. CONCLUSIONS: Hemi-ablation of the prostate with WST11 vascular targeted photodynamic therapy was well tolerated and resulted in a negative biopsy in the treated lobe in the majority of men. Dosing parameters and the light dose index appear related to tissue response as determined by magnetic resonance imaging and biopsy. These parameters may serve as the basis for further prospective studies.
Authors: Duke Bahn; Andre Luis de Castro Abreu; Inderbir S Gill; Andrew J Hung; Paul Silverman; Mitchell E Gross; Gary Lieskovsky; Osamu Ukimura Journal: Eur Urol Date: 2012-03-21 Impact factor: 20.096
Authors: Hashim U Ahmed; Viktor Berge; David Bottomley; William Cross; Rakesh Heer; Richard Kaplan; Tom Leslie; Chris Parker; Clare Relton; Richard Stephens; Matthew R Sydes; Lindsay Turnbull; Jan van der Meulen; Andrew Vickers; Timothy Wilt; Mark Emberton Journal: Nat Rev Clin Oncol Date: 2014-04-22 Impact factor: 66.675
Authors: Masoom A Haider; Sean R H Davidson; Ashwini V Kale; Robert A Weersink; Andrew J Evans; Ants Toi; Mark R Gertner; Arjen Bogaards; Brian C Wilson; Joseph L Chin; Mostafa Elhilali; John Trachtenberg Journal: Radiology Date: 2007-05-16 Impact factor: 11.105
Authors: Sean R H Davidson; Robert A Weersink; Masoom A Haider; Mark R Gertner; Arjen Bogaards; David Giewercer; Avigdor Scherz; Michael D Sherar; Mostafa Elhilali; Joseph L Chin; John Trachtenberg; Brian C Wilson Journal: Phys Med Biol Date: 2009-03-20 Impact factor: 3.609
Authors: Hashim U Ahmed; Richard G Hindley; Louise Dickinson; Alex Freeman; Alex P Kirkham; Mahua Sahu; Rebecca Scott; Clare Allen; Jan Van der Meulen; Mark Emberton Journal: Lancet Oncol Date: 2012-04-17 Impact factor: 41.316
Authors: Ian A Donaldson; Roberto Alonzi; Dean Barratt; Eric Barret; Viktor Berge; Simon Bott; David Bottomley; Scott Eggener; Behfar Ehdaie; Mark Emberton; Richard Hindley; Tom Leslie; Alec Miners; Neil McCartan; Caroline M Moore; Peter Pinto; Thomas J Polascik; Lucy Simmons; Jan van der Meulen; Arnauld Villers; Sarah Willis; Hashim U Ahmed Journal: Eur Urol Date: 2014-10-01 Impact factor: 20.096
Authors: Jonathan B Bloom; Samuel A Gold; Graham R Hale; Kareem N Rayn; Vikram K Sabarwal; Ivane Bakhutashvili; Vladimir Valera; Baris Turkbey; Peter A Pinto; Bradford J Wood Journal: Gland Surg Date: 2018-04
Authors: Inderbir S Gill; Abdel-Rahmene Azzouzi; Mark Emberton; Jonathan A Coleman; Emmanuel Coeytaux; Avigdor Scherz; Peter T Scardino Journal: J Urol Date: 2018-06-02 Impact factor: 7.450
Authors: Alejandra Martinez de Pinillos Bayona; Josephine H Woodhams; Hayley Pye; Rifat A Hamoudi; Caroline M Moore; Alexander J MacRobert Journal: Cancer Lett Date: 2017-02-20 Impact factor: 8.679
Authors: Giuseppe Fallara; Paolo Capogrosso; Paolo Maggio; Alessandro Taborelli; Francesco Montorsi; Federico Dehò; Andrea Salonia Journal: Int J Impot Res Date: 2020-09-30 Impact factor: 2.896
Authors: Juan Zhang; Chengshi Jiang; João Paulo Figueiró Longo; Ricardo Bentes Azevedo; Hua Zhang; Luis Alexandre Muehlmann Journal: Acta Pharm Sin B Date: 2017-09-22 Impact factor: 11.413